Synonyms
Status
Molecule Category Free-form
ATC N06AB06
UNII QUC7NX6WMB
EPA CompTox DTXSID6023577

Structure

InChI Key VGKDLMBJGBXTGI-SJCJKPOMSA-N
Smiles CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
InChI
InChI=1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C17H17Cl2N
Molecular Weight 306.24
AlogP 5.18
Hydrogen Bond Acceptor 1.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 2.0
Polar Surface Area 12.03
Molecular species BASE
Aromatic Rings 2.0
Heavy Atoms 20.0
Assay Description Organism Bioactivity Reference
Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT None 25.0 nM
Equilibrium dissociation constant (KD) for Competitive binding between [3H]- nisoxatine and the compound at human Norepinephrine transporter None 420.0 nM
In vitro inhibition of serotonin (5-HT) uptake in crude rat brain synaptosomes Rattus norvegicus 60.0 nM
Inhibition of 5-HT uptake in synaptosomal preparation from rat corpus striatum, using [3H]5-HT Rattus norvegicus 60.0 nM Inhibition of 5-HT uptake in synaptosomal preparation from rat corpus striatum, using [3H]5-HT Rattus norvegicus 460.0 nM
Inhibition of dopamine uptake in synaptosomal preparation in rat corpus striatum, using [3H]dopamine None 320.0 nM
Inhibition of norepinephrine uptake in synaptosomal preparation fro rat hypothalamus, using [3H]norepinephrine None 300.0 nM
Inhibition of [3H]- DA reuptake into rat striatal synaptosomes None 260.0 nM
Inhibition of [3H]- NE reuptake into rat hippocampal synaptosomes None 220.0 nM
Inhibition of [3H]5-HT reuptake into rat frontal cortex synaptosomes None 3.4 nM
Inhibition of the uptake of tritiated dopamine (DA) in rat synaptosomes None 78.3 nM
Inhibition of uptake of tritiated norepinephrine (NE) in rat synaptosomes None 159.0 nM
Inhibition the uptake of tritiated serotonin (5-HT) by the serotonin transporter SERT in rat synaptosomes None 0.85 nM
Equilibrium dissociation constant (KD) for Competitive binding between [3H]- imipramine and the compound at human transporter-hSERT None 0.29 nM
Inhibition of serotonin re-uptake at human serotonin transporter expressed in HEK293 cells Homo sapiens 3.0 nM
Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells Homo sapiens 310.0 nM
Inhibition of noradrenaline re-uptake at human noradrenaline transporter expressed in HEK293 cells Homo sapiens 825.0 nM
Inhibition of HSP90 expressed in HEK293 cells assessed as reduction of HSP90-eEF2K signaling complex by EYFP and/or YFP Venus fragment based reporter gene assay None 50.0 %
Inhibition of [3H]serotonin reuptake at human SERT expressed in HEK293 cells by scintillation counting Homo sapiens 3.0 nM
Inhibition of [3H]norepinephrine reuptake at human NET expressed in MDCK cells by scintillation counting Homo sapiens 825.0 nM
Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting Homo sapiens 310.0 nM
Inhibition of CYP2C19 None 310.0 nM
Inhibition of CYP3A4 None 800.0 nM
DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) None 310.2 nM
DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) None 984.0 nM
DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) None 366.9 nM
DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) None 507.3 nM DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) None 364.5 nM
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) None 783.1 nM
DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) Rattus norvegicus 605.0 nM DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) Rattus norvegicus 334.9 nM
DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) None 288.8 nM DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) None 108.3 nM
DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) None 181.4 nM DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) None 82.8 nM
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) None 650.5 nM
DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) None 984.8 nM DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) None 976.6 nM
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) None 567.3 nM
DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) None 0.141 nM DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) None 0.075 nM
DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol) None 69.7 nM DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol) None 29.3 nM
DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) None 32.4 nM DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) None 25.8 nM
Binding affinity to sigma 1 receptor None 57.0 nM
DNDI: HAT in Vitro, 72 hour Trypanosoma brucei rhodesiense 770.0 nM
DNDI: Malaria in Vitro, 72 hour Plasmodium falciparum 510.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 10.56 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.42 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.42 %
Inhibition of glycoprotein in VSV-G pseudotyped EBOV Mayinga infected in human HEK293T cells assessed as reduction in virus entry preincubated with pseudotyped virus for 1 hr followed by cell infection and measured after 48 hrs by luciferase reporter gene assay Ebolavirus 700.0 nM
Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in Sprague-Dawley rat brain membranes by scintillation counting method Rattus norvegicus 57.0 nM
Inhibition of SERT (unknown origin) Homo sapiens 0.19 nM

Related Entries

Environmental Exposure

Countries
Croatia
Czech Republic
Germany
Hungary
Romania
Serbia
Slovakia
Slovenia
Sweden
USA

Cross References

Resources Reference
ChEBI 9123
ChEMBL CHEMBL809
DrugBank DB01104
DrugCentral 2436
FDA SRS QUC7NX6WMB
Human Metabolome Database HMDB0005010
Guide to Pharmacology 4798
KEGG C07246
PDB SRE
PharmGKB PA451333
PubChem 68617
SureChEMBL SCHEMBL28701
ZINC ZINC000001853550